Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, et al.
Nature (2023) Vol. 623, Iss. 7987, pp. 594-600
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Long COVID: a clinical update
Trisha Greenhalgh, Manoj Sivan, Alice Perlowski, et al.
The Lancet (2024) Vol. 404, Iss. 10453, pp. 707-724
Closed Access | Times Cited: 88
Prevalence of persistent SARS-CoV-2 in a large community surveillance study
Mahan Ghafari, Matthew Hall, Tanya Golubchik, et al.
Nature (2024) Vol. 626, Iss. 8001, pp. 1094-1101
Open Access | Times Cited: 74
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
William HK Schilling, Podjanee Jittamala, James A Watson, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 1, pp. 36-45
Open Access | Times Cited: 60
Evolution of the SARS-CoV-2 Mutational Spectrum
Jesse D. Bloom, Annabel C. Beichman, Richard A. Neher, et al.
Molecular Biology and Evolution (2023) Vol. 40, Iss. 4
Open Access | Times Cited: 52
The One Health Concept
S. Pitt, Alan Gunn
British Journal of Biomedical Science (2024) Vol. 81
Open Access | Times Cited: 37
The Emergence and Evolution of SARS-CoV-2
Edward C. Holmes
Annual Review of Virology (2024) Vol. 11, Iss. 1, pp. 21-42
Closed Access | Times Cited: 32
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Joseph F. Standing, Laura Buggiotti, José Afonso Guerra‐Assunção, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 21
Learning from Protein Engineering by Deconvolution of Multi‐Mutational Variants
Frank Hollmann, Joaquin Sanchis, Manfred T. Reetz
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 36
Open Access | Times Cited: 18
Orthogonal RNA replication enables directed evolution and Darwinian adaptation in mammalian cells
Liang Ma, Yihan Lin
Nature Chemical Biology (2025)
Closed Access | Times Cited: 2
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 36
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections
Mohammed Nooruzzaman, Katherine Johnson, Ruchi Rani, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 13
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study
Nicholas M. Fountain‐Jones, Robert Vanhaeften, Jan Williamson, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 5, pp. e452-e458
Open Access | Times Cited: 12
A ~40-kb flavi-like virus does not encode a known error-correcting mechanism
Mary E. Petrone, Joe Grove, Julien Mélade, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 30
Open Access | Times Cited: 12
Targeting the SARS-CoV-2 reservoir in long COVID
Amy D. Proal, Soo Aleman, Morgane Bomsel, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo
Taha Y. Taha, Rahul K. Suryawanshi, Irene P. Chen, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 8, pp. e1011614-e1011614
Open Access | Times Cited: 20
Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study
Salvatore Rotundo, Lavinia Berardelli, Sara Palma Gullì, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model
Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen, et al.
Science Advances (2024) Vol. 10, Iss. 35
Open Access | Times Cited: 7
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Emerging Trends of Gold Nanostructures for Point-of-Care Biosensor-Based Detection of COVID-19
Akhilesh Kumar Yadav, Nagaraj Basavegowda, Saba Shirin, et al.
Molecular Biotechnology (2024)
Closed Access | Times Cited: 5
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 5
Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study
Christina Van Heer, S. S. Majumdar, Indra Parta, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 41, pp. 100917-100917
Open Access | Times Cited: 12
Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection
Christopher J. R. Illingworth, José Afonso Guerra‐Assunção, Samuel Gregg, et al.
Virus Evolution (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top